CARGO Therapeutics (CRGX) Projected to Post Earnings on Thursday

CARGO Therapeutics (NASDAQ:CRGX) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect CARGO Therapeutics to post earnings of ($0.95) per share for the quarter.

CARGO Therapeutics Price Performance

Shares of CRGX opened at $4.11 on Tuesday. The firm’s 50 day simple moving average is $6.94 and its 200 day simple moving average is $14.45. The company has a market capitalization of $189.27 million, a P/E ratio of -0.96 and a beta of 1.65. CARGO Therapeutics has a 1-year low of $3.00 and a 1-year high of $32.79.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CRGX. Piper Sandler downgraded shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $34.00 to $4.00 in a research note on Thursday, January 30th. Jefferies Financial Group downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $3.00 in a research note on Thursday, January 30th. Chardan Capital downgraded shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Thursday, January 30th. Finally, William Blair downgraded shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to data from MarketBeat, CARGO Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $15.00.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.